Six‐Membered Aromatic Nitrogen Heterocyclic Anti‐Tumor Agents: Synthesis and Applications

J Li, A Gu, XM Nong, S Zhai, ZY Yue… - The Chemical …, 2023 - Wiley Online Library
Cancer stands as a serious malady, posing substantial risks to human well‐being and
survival. This underscores the paramount necessity to explore and investigate novel …

Receptor tyrosine kinases: Biological functions and anticancer targeted therapy

N Zhang, Y Li - Medcomm, 2023 - Wiley Online Library
Receptor tyrosine kinases (RTKs) are a class of protein kinases that play crucial roles in
various cellular processes, including cell migration, morphological differentiation, cell …

Regulatory network of ferroptosis and autophagy by targeting oxidative stress defense using sulfasalazine in triple-negative breast cancer

T Takatani-Nakase, C Ikushima, M Sakitani, I Nakase - Life Sciences, 2024 - Elsevier
Aims The cellular defense system against oxidative stress is important for the survival ability
and sensitization in chemotherapy; however, the regulatory mechanisms remain unknown in …

Adaptive boost approach for possible leads of triple-negative breast cancer

G Chen, H He, L Zhao, KB Chen, S Li… - … and Intelligent Laboratory …, 2022 - Elsevier
Recent research has shown that cyclin dependent kinase 7 (CDK7), cyclin dependent
kinase 9 (CDK9) and cyclin T1 (CCNT1) can assist transcriptional misregulation in cancer …

Targeting receptor tyrosine kinases as a novel strategy for the treatment of triple-negative breast cancer

SK Jaradat, NM Ayoub, AH Al Sharie… - Technology in Cancer …, 2024 - journals.sagepub.com
Triple-negative breast cancer (TNBC) comprises a group of aggressive and heterogeneous
breast carcinoma. Chemotherapy is the mainstay for the treatment of triple-negative tumors …

[HTML][HTML] Small molecule agents for triple negative breast cancer: Current status and future prospects

Y Ou, M Wang, Q Xu, B Sun, Y Jia - Translational Oncology, 2024 - Elsevier
Triple-negative breast cancer (TNBC) is a subtype of breast cancer with poor prognosis. The
number of cases increased by 2.26 million in 2020, making it the most commonly diagnosed …

YB-1 activating cascades as potential targets in KRAS-mutated tumors

S Khozooei, S Veerappan, M Toulany - Strahlentherapie und Onkologie, 2023 - Springer
Abstract Y‑box binding protein‑1 (YB-1) is a multifunctional protein that is highly expressed
in human solid tumors of various entities. Several cellular processes, eg cell cycle …

[HTML][HTML] Integrated single-cell and bulk RNA sequencing analysis identifies a neoadjuvant chemotherapy-related gene signature for predicting survival and therapy in …

X Zhang, R Feng, J Guo, L Pan, Y Yao, J Gao - BMC Medical Genomics, 2023 - Springer
Neoadjuvant chemotherapy (NAC) is a well-established treatment modality for locally
advanced breast cancer (BC). However, it can also result in severe toxicities while …

[HTML][HTML] Integrins and Actions of Androgen in Breast Cancer

CC Tsai, YCSH Yang, YF Chen, LY Huang, YN Yang… - Cells, 2023 - mdpi.com
Androgen has been shown to regulate male physiological activities and cancer proliferation.
It is used to antagonize estrogen-induced proliferative effects in breast cancer cells …

Ononin inhibits triple-negative breast cancer lung metastasis by targeting the EGFR-mediated PI3K/Akt/mTOR pathway

K Ganesan, C Xu, J Wu, B Du, Q Liu, Y Sui… - Science China Life …, 2024 - Springer
The spreading of cancer cells from the primary tumor site to other parts of the body, known
as metastasis, is the leading cause of cancer recurrence and mortality in patients with triple …